- On September 29, 2023 the FDA updated guidance moving 19 compounds (mostly peptides) off the Category 1 compounding list, which forced many compounding pharmacies to stop supplying those peptides to patients almost immediately .
- Clinicians report no submitted adverse safety signals from the FDA to justify that reclassification; a lawsuit by compounding stakeholders demanded the FDA produce safety evidence and the FDA was unable to produce case reports or series supporting the ban .
- The reclassification is being contested legally and is widely regarded in this discussion as an arguably unlawful regulatory move that has pushed physicians into public‑policy advocacy around patient access to compounded medicines.
Non-technical mechanism: why peptides escaped full FDA approval historically
- Many therapeutically interesting peptides are naturally occurring human peptides, discovered in human biology, and could not be patented as human genes or naturally occurring products after Supreme Court precedent limiting patenting of natural human genes; that lack of strong patent protection removed the commercial incentives needed for full FDA approval and large‑scale pharmaceutical development .
- Before the 2023 action, those peptides were largely accessed via compounding under FDA Category 1 interim guidance put in place after the 2014 compounding reforms (post–New England Compounding Center) .
- The vast majority of peptide active pharmaceutical ingredients (APIs) and many finished peptide products in the current market are manufactured in China; this is described as the dominant global source for peptide APIs and a broader dependency for many drugs' raw materials
- That offshore concentration contributed to drug shortages (e.g., ICU antibiotics and vasopressors) seen during the COVID-19 era and is the structural reason physicians and some advocates are pushing to onshore API production to improve reliability and quality control .
- Exceptions exist: large pharmaceutical manufacturers (example cited: Eli Lilly in Indianapolis) have onshored much of their GLP-1 API production for drugs like semaglutide (brand examples discussed) while many other peptides circulating in the research/gray market still rely on overseas supply .
- The FDA historically used a 40‑amino‑acid threshold in the alpha chain as an industry standard cutoff for classifying a product as a biologic versus a "simple" peptide; peptides above that threshold are treated as biologics requiring a Biologics License Application (BLA) .
- Tirzepatide (discussed as “retatride/retoride” in the conversation) has 39 amino acids in the alpha chain but contains additional modifications (fatty‑acid side chains and two extra amino acids attached off the alpha chain) — the manufacturer argues that functionally the molecule should be treated as a biologic (their legal argument: 39 + 2 = 41), while the FDA stuck to the 39‑residue rule initially
- A court vacated the FDA’s decision and remanded the classification for re‑examination; the ultimate designation matters greatly because biologic status requires an expensive BLA (estimated $80–$120 million) and confers exclusivity (12 years), which would block compounding and generics and allow much higher prices versus small‑molecule/peptide competition
- If a drug is treated as a biologic, the manufacturer can maintain exclusivity and sustained high prices similar to established biologics (e.g., Humira still costs roughly $11,000/month cash historically) because biosimilars are difficult to bring to market and pricing dynamics differ sharply from small‑molecule generics
- If classified as a peptide/small molecule, competition (including compounding and generics) could meaningfully lower cash prices (examples discussed: semaglutide cash pricing >$1,000/month historically vs. some lower‑cost programs down to ~$149–$349/month) — though exact future pricing is speculative and dependent on policy and market forces
- Physicians in this space have felt forced into public‑policy involvement because regulatory choices directly change patient care options; the guest describes moving into public messaging and advocacy not as partisan politics but as patient advocacy to restore access and ensure onshoring and quality supply chains
- Two peptides discussed as more likely to have oral forms are BPC‑157 and KPV; arginate salts of BPC‑157 are mentioned as the oral form while acetate is used for injection, and oral administration is believed to produce a more gut‑centric effect while subcutaneous injection produces more systemic exposure .
- Many other peptides (and peptide‑adjacent small molecules like ibutamoren/MK‑677) exist in the market; ibutamoren is a non‑peptide small molecule that acts on growth‑hormone pathways and is not chemically a peptide .
- Large‑scale oncologic signals typically surface only after widespread deployment and are monitored by real‑world evidence (post‑market surveillance); historically, even heavy exogenous growth‑hormone exposure (e.g., in bodybuilding) has not produced clear cancer signals in the available evidence according to the guest’s statement, though metabolic effects like insulin resistance have been observed and need management .
- The guest strongly rejects fear‑mongering that equates peptide use or growth‑hormone secretagogues with definitive cancer risk in the absence of concrete data, while acknowledging rare or theoretical risks and the need for proper monitoring and evidence collection
- Matric (referred to in the discussion as "Matsi" / "Mi") is described as an adjunct that may counteract GLP‑1 induced low energy and support endurance performance by upregulating energy production and possibly being muscle‑sparing through CK2 activity; it is touted as a useful adjuvant to GLP‑1 therapy for certain patients and athletes, though broader access hinges on compound availability and regulatory status
- Clinicians are layering peptides and peptide‑adjacent compounds (e.g., GLP‑1s plus agents that act on androgen or metabolic axes) to optimize weight loss, energy, and preserve lean mass — but combination use requires careful monitoring and individualized dosing .
- The guest advises against routine use of carterine because early data showed some cancer signals even at comparatively low/high doses in animal studies or trials; he frames its risk/benefit as unfavorable for most people except possibly select elite endurance athletes in tightly controlled, short‑term scenarios
- Not everyone on exogenous testosterone requires hCG, but every patient on testosterone should be informed about hCG and consider it in certain situations (three main reasons given): fertility preservation or future desire for children; maintaining endogenous testosterone production potential; and preserving testicular size and neurosteroid production (precursors like pregnenolone and allopregnanolone) that can influence mood, libido, and emotional well‑being
- hCG forms differ: recombinant hCG (pharmacy recombinant products) tends to be more potent than urinary hCG (used commonly by compounding pharmacies in practice), and dosing practices vary by physician preference and formulation .
- Practical dosing example from the guest: to maintain testicular size and fertility while on testosterone, a commonly used regimen is 500 IU hCG three times weekly (though many patients prefer less frequent dosing, which is suboptimal given hCG’s ~36‑hour half‑life) and clinicians must monitor for increased aromatization (estrogen conversion) and adjust exogenous testosterone dose accordingly .
- More frequent, lower‑dose testosterone administration (e.g., twice or three times per week, or even daily subcutaneous microdosing) tends to reduce peak‑to‑trough fluctuations that drive aromatization (conversion to estrogen) and polycythemia (increased hematocrit), which can allow higher total weekly dosing with fewer side effects compared to infrequent large bolus injections
- The guest personally prefers frequent dosing (reports daily subcutaneous injections in his regimen) and notes that commercially available oral testosterone undecanoate formulations (e.g., Jatenzo, Tando) produce steadier daily exposure and historically show favorable profiles for aromatization and hematocrit compared with infrequent depot injections .
- Testosterone therapy can worsen or unmask obstructive sleep apnea in susceptible men; clinicians should screen with brief tools such as the STOP‑BANG questionnaire before or during therapy and pursue sleep evaluation if risk is present .
- Other common TRT‑related adverse effects include hairline recession (in predisposed individuals) and possible skin oiliness/acne; hematologic monitoring (hematocrit) is necessary because testosterone can raise red‑cell mass (polycythemia) .
- To support steroid intermediates and neurosteroid pathways suppressed by exogenous testosterone, physicians sometimes add DHEA and pregnenolone; some clinicians are also exploring low‑dose progesterone in certain men (e.g., topical low doses ~5 mg cited by an interlocutor), though this is less established in conventional male fertility practice and remains an area of practitioner variability and interest
- Secretagogues and peptides that increase GH (e.g., CJC‑class peptides, sermorelin analogs) can produce metabolic effects including insulin resistance when pushed to high exposures; combining them with metabolic modulators (e.g., GLP‑1s, tirzepatide analogs) is being explored to balance effects, but dosing and long‑term consequences require careful monitoring in practice
- For length: the only demonstrably safe method with consistent small gains is a mechanical traction device that applies steady tension over time (not "jelqing" or weighted hanging); expected gains in length from validated traction protocols are modest — roughly 1–2 cm in many reports, with occasional larger responders
- For girth: many historical surgical or implant approaches have had inconsistent outcomes or serious complications (fat grafting can produce lumpy results; subcutaneous silicone implant devices have caused severe complications and class‑action litigation) .
- The safest, reproducible girth enhancement with published outcomes is injectable hyaluronic acid (HA) filler placed in specific anatomic planes (between Buck’s and Dartos fascia) with technique modifications (small aliquot layering, compression sleeve post‑procedure to limit migration) to improve durability and cosmetic results; typical per‑treatment increments are ~0.25 inch of girth per described treatment series with multiple syringes, and a common practical program is serial treatments (e.g., six syringes per session, repeated over several sessions) achieving ~1 inch total girth increase over a 12‑week course in many patients
- HA filler results are not permanent; maintenance “booster” injections at intervals (e.g., around every 18 months) are commonly used to preserve results in published clinical series and retrospective reviews assessing safety, efficacy, and satisfaction .
- The clinician stresses that cosmetic interventions cannot resolve underlying psychological issues such as body dysmorphia, depression, or deep insecurity; genital augmentation should be considered a "nice to have" that complements psychological acceptance, not a cure for emotional or relational problems
- Informed consent should include realistic expectations about the magnitude of change (small‑to‑moderate length gains, meaningful but delimited girth increases) and the possibility of additional procedures or revisions if complications or dissatisfaction arise
- The guest frames his practice as harm‑reduction oriented for appearance/performance medicine (e.g., assisting bodybuilders using anabolic steroids to minimize health harms) while avoiding provision of illicit sources of gear; he advocates patient education, monitoring, and mitigating risks rather than moralizing drug use .
- He emphasizes evidence and monitoring over fear‑based messaging and encourages collection of real‑world data to detect adverse signals early after deployment of new therapeutics, because RCTs alone can miss later, rarer harms that only show up with broad population exposure .
- Screen men for sleep apnea risk before/after starting TRT using STOP‑BANG and refer for sleep study if risks are present .
- Discuss fertility goals before initiating long‑term testosterone; consider hCG (typical fertility‑preserving regimens: e.g., 500 IU hCG three times weekly as a clinical regimen used to maintain testicular size/fertility) and counsel about the limitations and monitoring required
- If a patient requests penile cosmetic procedures, offer evidence‑based options: traction devices for modest length gains and hyaluronic acid girth injections performed by experienced clinicians with proper post‑procedure care; counsel about realistic outcomes, maintenance, and psychological expectations
- The legal classification of newer peptide therapeutics (peptide vs biologic) remains unsettled and will decide compounding access, pricing, and whether generics/biosimilars and compounders can lawfully supply alternatives; the final regulatory decisions and subsequent litigation will determine market structure and patient access
- Long‑term safety profiles for many off‑label or compounded peptides remain incompletely characterized in humans; the lack of reported adverse events in compounding use prior to the crackdown is contested, and robust, prospective real‑world surveillance would better define true long‑term risks (oncologic, metabolic, cardiovascular)
- Head‑to‑head comparative effectiveness (and cost‑effectiveness) between competing obesity/metabolic agents (e.g., tirzepatide analogs vs. other GLP‑1s or GLP‑1/GIP combinations) and the role of adjuncts like matric/MI in preserving lean mass need more controlled clinical trials to clarify optimal combinations, sequencing, and safety profiles
- If fertility or future endogenous testosterone matters: learn about hCG and discuss preservation strategies with your clinician before starting TRT .
- If you’re on TRT: consider more frequent, lower‑dose injections (multiple times per week or daily microdoses) to reduce peaks that drive estrogen conversion and polycythemia; monitor hematocrit and symptoms closely
- For penile enhancement: traction devices can produce modest length gains (~1–2 cm), and hyaluronic acid injections can increase girth meaningfully (aggregate ≈1 inch over serial sessions with ~0.25 in per treatment increments reported), but maintain realistic expectations and address psychological factors first
- Advocate for improved domestic API manufacturing and regulatory clarity if you care about access and quality of peptide medicines; policy decisions (FDA classification and compounding rules) will materially affect price and availability
Last edited:
Start Here (2K views)
